Company Product Description Indication Status
Bristol Myers Squibb Co., of New York Inrebic (fedratinib) Wild-type and mutationally activated JAK2 and FMS-like tyrosine kinase 3 inhibitor Newly diagnosed and previously treated myelofibrosis The European Commission granted full marketing authorization in all EU member states as well as Norway, Iceland and Liechtenstein
China Oncology Focus Ltd., of Hong Kong, an affiliate of Lee's Pharmaceutical Holdings Ltd., and Sorrento Therapeutics Inc., of San Diego Socazolimab Anti-PD-L1 antibody Recurrent or metastatic cervical cancer Received breakthrough therapy designation in China 
Immunomet Therapeutics Inc., of Houston IM-156 Protein complex 1 inhibitor Idiopathic pulmonary fibrosis FDA cleared the IND application and granted orphan drug designation
Navidea Biopharmaceuticals Inc., of Dublin, Ohio Tc99m tilmanocept Imaging agent Rheumatoid arthritis Submitted its formal type B meeting request to the FDA; the agency will now review the briefing documents containing results from the NAV3-31 phase IIb study and the proposed phase III design and protocol
Russian Direct Investment Fund, of Moscow, Astrazeneca plc, of Cambridge, U.K., and University of Oxford Sputnik V and COVID-19 Vaccine Astrazeneca  Vaccines COVID-19 prophylaxis The Ministry of Health of Azerbaijan issued a permit to conduct clinical trials of a combined use of the 2 vaccines; trials will begin at the end of February
Russian Direct Investment Fund, of Moscow Sputnik V COVID-19 spike glycoprotein modulator COVID-19 prophylaxis Mongolia granted emergency use authorization; approved under the emergency use authorization procedure in Pakistan
Triastek Inc., of Nanjing, China T-19 3D-printed drug product that functions as a chronotherapeutic drug delivery system Rheumatoid arthritis FDA approved the IND 505(b)(2) application 

Notes

For more information about individual companies and/or products, see Cortellis.